Celgene International Sárl Release: Initial Phase 3 Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at American Socie

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST® (Frontline Investigation of Lenalidomide + Dexamethasone Versus Standard Thalidomide), its phase III study (MM-020/IFM 07-01) of REVLIMID® (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) ineligible for stem cell transplant will be presented on Sunday, Dec. 8 during the plenary session of the 55th American Society of Hematology annual meeting in New Orleans, La.

Help employers find you! Check out all the jobs and post your resume.